40
Participants
Start Date
December 31, 2008
Primary Completion Date
July 31, 2009
Study Completion Date
July 31, 2009
esreboxetine
Once daily administration of 4mg esreboxetine for 3 days, followed by 8mg esreboxetine for 3 days, followed by 10mg esreboxetine for 3 days. Drug will be administered double-blind.
placebo
Once daily administration of placebo for 9 days. Placebo will be administered double blind
moxifloxacin
Once daily administration of placebo for 8 days followed by open label single oral dose of 400mg moxifloxacin on day 9
Pfizer Investigational Site, Brussels
Lead Sponsor
Pfizer
INDUSTRY